Published in Cancer Weekly, March 14th, 2000
"Successful endocrine therapy in breast cancer is frequently characterized by effective pharmacological suppression of tumor ER protein activity," wrote T.A. Madden et al. "To ascertain if a genetic approach could be similarly effective in downregulating the activities of the ER, we have transfected ER positive, MCF-7 cells, and ER negative but ER transfected COS-7 cells with: 1) chimeric methylphosphonate phosphodiester antisense oligonucleotides (ODNs) complementary to the 5' end of human ER mRNA; 2) two ER antisense RNA expression vectors containing 1.1kb or 1.8kb coding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.